Johnson & Johnson 3Q Revenues: $20.3 billion (+4%) 3Q Earnings: $3.9 billion (+5%) YTD Revenues: $61.2 billion (+9%) YTD Earnings: $12.3 billion (+2%) Comments: Pharmaceutical sales were $10.3 billion in the quarter, up 7%.  Domestic sales increased 5%,  and international sales increased 10%, which reflected an operational increase of 13% and a negative currency impact of 4%. Remicade sales were down 16% to $1.4 billion, due to competition. Simponi sales were up 13% to $536 million. Ste...